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a  b  s  t  r  a  c  t
Nocardia is an opportunistic pathogen that causes respiratory infections in immunocompro-
mised patients. The aim of this study was to analyze the epidemiology, clinical signiﬁcance
and  antimicrobial susceptibility of Nocardia species isolated from eight children with cys-
tic  ﬁbrosis. The isolated species were identiﬁed as Nocardia farcinica, Nocardia transvalensis,
Nocardia pneumoniae,  Nocardia veterana and Nocardia wallacei. N. farcinica was isolated in three
patients and all of them presented lung affectation with a chronic colonization and pneu-
monia. N. farcinica showed resistance against gentamicin, tobramycin, cefotaxime, but was
susceptible to trimethoprim-sulfamethoxazole and amikacin. N. transvalensis, which was
isolated from two patients, showed an association with chronic colonization. N. transvalensis
was  resistant to tobramycin and amikacin, but susceptible to ciproﬂoxacin, trimethoprim-
sulfamethoxazole and cefotaxime. N. veterana, N. pneumoniae and N. wallacei were isolated
from  three different patients and appeared in transitory lung colonization. N. veterana and
N.  pneumoniae were susceptible to imipenem, trimethoprim-sulfamethoxazole, amikacin,
tobramycin, and cefotaxime. N. wallacei was resistant to amikacin, tobramycin, imipenem,
and  trimethoprim-sulfamethoxazole and susceptible to ciproﬂoxacin and cefotaxime. All
the  isolates were identiﬁed up to species level by 16S rRNA gene sequencing. The presence
of  Nocardia in the sputum of patients with cystic ﬁbrosis is not always an indication of an
active infection; therefore, the need for a treatment should be evaluated on an individ-
ual  basis. The detection of multidrug-resistant species needs molecular identiﬁcation and
susceptibility testing, and should be performed for all Nocardia infections.©  2016 Sociedade Brasileira de Microbiologia. Published by Elsevier Editora Ltda. This isan  open access arti
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Introduction
Cystic ﬁbrosis (CF) is a common autosomal recessive disorder
caused by mutation in the CF transmembrane conductance
regulator gene.1 The most important complication of CF
is a chronic bacterial infection and a concomitant airway
inﬂammation, mostly caused by Staphylococcus aureus and
Pseudomonas aeruginosa.2 In purview of this information, an
isolation of Nocardia from the respiratory tract of patients
with CF is an uncommon ﬁnding; and there are very few
reports in the literature about this. Thorn et al.,3 for exam-
ple, have recently reported in the United States that Nocardia
asteroides was the most incident species found in 13 out of
17 studied patients, while other isolated species were Nocar-
dia farcinica, Nocardia transvalensis, Nocardia cyriacigeorgica and
Nocardia otitidiscaviarum. Despite their presence in the spu-
tum, the clinical signiﬁcance of these microorganisms in CF
patients is considered uncertain,4–6 as their isolation does not
necessarily imply an infection and should be considered indi-
vidually in the clinical context of an individual patient.7
Nocardiae are aerobic actinomycetes ubiquitous in soil
and aquatic habitats. Nocardia are beaded, branching Gram-
positive rods that are partially acid-fast and generally slow
growing. The genus Nocardia contains more  than 100 described
species8; and about 30 of them are known to cause diseases
in human.9 The microorganism was ﬁrst described by Nocard
in 1888 as a fungus but was later classiﬁed as an aerobic bac-
terium under the genus Nocardia, and order Actinomycetales.10
Nocardia spp. are able to produce infections such as myce-
tomas, nodular lymphangitic syndrome, and pneumonia in
immunocompromised patients, where pneumonia is most
frequently observed. There are possibilities of the dissemina-
tion of a primary pulmonary infection to almost every organ.11
The main aim of this study was to identify Nocardia iso-
lates obtained from Spanish children with cystic ﬁbrosis at a
species level, test their antimicrobial susceptibility, and assess
the clinical signiﬁcance.
Material  and  methods
Nocardia spp. were isolated in eight out of 37 patients being fol-
lowed between 1995 and 2008 in the CF unit of Miguel Servet
Hospital. Zaragoza. Spain. Sputum specimens were collected
from patients coming for a routine microbiological inves-
tigation, and the samples were grown on common culture
media (sheep blood agar, chocolate agar, MacConkey agar and
Sabouraud chloramphenicol agar plates all from Oxoid (UK).12
All spontaneous sputa were subjected to Gram staining.13 In
the case, when Gram-positive branching ﬁlamentous orga-
nisms were observed, the sample was inoculated onto an
additional plate of buffered charcoal yeast extract agar. All
plates were incubated for 14 days before being discarded as
negative.The evaluated variables were age, sex, clinical manifes-
tations, underlying treatment, clinical course and additional
organisms isolated from the patients infected or colonized by
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The identiﬁcation of a microorganism as member of the
genus Nocardia was based on macroscopic, microscopic, and
biochemical characteristics (physical features of colonies,
microscopic morphology and Gram and modiﬁed acid-fast
staining, casein, xanthine and tyrosine hydrolysis, opaciﬁca-
tion of Middlebrook 7H10 agar, arylsulfatase production after
14 days of incubation) as described by Boiron et al.14
The susceptibility of the isolates to different antimi-
crobials was determined by broth microdilution method,
as recommended by the CLSI for antimicrobial suscepti-
bility testing of Nocardiae.15 Appropriate dilutions for MIC
determinations were obtained by employing EMIZA 9EF
Sensititre® plates (Izasa). The recommended control refer-
ence strains (Escherichia coli ATCC® 35218 and S. aureus ATCC
29213®) were also used as positive controls. Susceptibility
testing was done with the recommended primary antimi-
crobials (amikacin, amoxicillin-clavulanic acid, ciproﬂoxacin,
imipenem, trimethoprim-sulfamethoxazole, and tobramycin)
and two secondary antimicrobials (cefotaxime and gentami-
cin). The plates were incubated at 37 ◦C for 72 h and read
manually with a mirrored box. The MICs were interpreted
according to CLSI.15
The species level identiﬁcation was done by sequencing a
606 bp long fragment of the 16S rRNA gene. DNA extraction,
PCR ampliﬁcation, and sequencing were carried out by using
primers Noc1 (5′-GCT TAA ACC ATG CAA GTCG-3′) and Noc2
(5′-GAA TTC CAG TCT CCC CTG-3′) as described previously.16
Each strain was sequenced in both the senses in order to deter-
mine a consensus sequence. To determine the percentage of
similarity to the closest type strain, each sequence was used
as a query using BLAST search against the GenBank database.
Results
Eight cases (2 male, 6 female; median age 13 years, range 10–17
years) of nocardial infections or colonization in CF patients
were diagnosed between 1995 and 2008.
The isolated Nocardia species were identiﬁed as N. farcinica
(3 cases, 100% of sequence similarity), N. transvalensis (2 cases,
100% of sequence similarity), Nocardia pneumoniae (1 case,
99% of sequence similarity), Nocardia veterana (1 case, 99%
of sequence similarity) and Nocardia wallacei (1 case, 100% of
sequence similarity). These isolates were tested for antimi-
crobial susceptibility; and their in vitro patterns of antibiotic
susceptibility are shown in Table 1.
N. farcinica could be isolated from three patients and
showed a rather typical multidrug resistance pattern, charac-
terized by resistance to cefotaxime, gentamicin, tobramycin;
susceptibility to amikacin, amoxicillin-clavulanic acid and
trimethoprim-sulfamethoxazole; and intermediate suscepti-
bility to imipenem; this was similar to previous reports for
the same species.17,18 The three patients having N. farcinica
infection were treated with trimethoprim-sulfamethoxazole,
although one of the isolates became resistant during the
treatment. The patients with N. farcinica presented lung affec-
tation with chronic colonization and pneumonia. Two of them
showed bronchiectasis in the course of disease evolution and
the other one showed a good clinical evolution.
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Table 1 – In vitro antimicrobial susceptibility patterns of Nocardia in CF patients.
MIC, g/mL (broth microdilution)
Antimicrobial agent N. farcinica N. transvalensis N. veterana N. pneumoniae N. wallacei
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 Patient 8
Amikacin ≤4 ≤4 ≤4 16 16 ≤4 ≤4 >8
Tobramycin >4 >4 >4 >4 >4 4 2 >8
Cefotaxime >16 >16 >16 2 2 0.5 1 4
Amoxicillin-clavulanic 8/4 8/4 8/4 ≤4/2 8/4 ≤4/2 ≤4/2 8/4
Imipenem 8 8 8 8 8 0.25 1 16
Ciproﬂoxacin >2 >2 >2 0.25 0.5 >2 >2 <0.25
Trimethoprim-sulfamethoxazole 0.5/9.5 >2/38 0.5/9.5 2/38 0.5/9.5 1/19 0.5/9.5 >4/76
Gentamicin >16 >16 >16 >16 >16 ≤4 ≤4 >16
Table 2 – Characteristics of CF patients.
Patient code Age (years)/sex Nocardia species Accompanying pathogens Clinical signiﬁcance Antibiotic
treatment
Clinical evolution
1 11/F N. farcinica S. aureus, H. inﬂuenzae Chronic colonizationa,
pneumonia
TMP-SMX, AMC Bronchiectasis
2 17/F N. farcinica P. aeruginosa,  S. apiospermum Colonization TMP-SMX No worsening
3 10/F N. farcinica S. aureus, P. aeruginosa Pneumonia AMK, TMP-SMX Severe
bronchiectasis.
Worsening
4 11/M N. transvalensis S. aureus, P. aeruginosa Chronic colonization TMP-SMX Dead 1998.
Massive
hemoptysis
5 10/F N. transvalensis S. aureus, P. aeruginosa Chronic colonization TMP-SMX Severe
bronchiectasis.
Worsening
6 16/M N. veterana S. aureus, P. aeruginosa Transient colonizationb None No worsening
7 15/F N. pneumoniae S. aureus, S. apiospermum Transient colonization None No worsening
8 16/F N. wallacei P. aeruginosa,  A. fumigatus Transient colonization AMC No worsening
F, female; M, male; TMP-SMX, trimethoprim-sulfamethoxazole; AMC, amoxicillin-clavulanic acid; AMK, amikacin.
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The susceptibility pattern of N. transvalensis was sim-
lar to the previously published data17 (Table 1). The
wo  patients with N. transvalensis presented an identical
usceptibility pattern and the same clinical signiﬁcance
chronic colonization) (Table 2). They were treated with
rimethoprim-sulfamethoxazole, and one died because of
assive hemoptysis.
N. veterana, N. pneumoniae, and N. wallacei were isolated
rom transitory lung colonization of three different patients.
hese patients showed improvement and only one child
equired antibiotic treatment (Table 2).
The demographic and clinical data of the patients are sum-
arized in Table 2. Among the eight patients with isolation
f Nocardia species, two (25%) had a clinical manifestations
pneumonia), and the other six (75%) only presented lung col-
nization. Other microorganisms isolated from the patients
ere: S. aureus,  P. aeruginosa,  Aspergillus fumigatus,  Scedosporium
piospermum and Haemophilus inﬂuenzae (Table 2).iscussion
ocardia can cause lung disease, skin disease, systemic dis-
rders involving the central nervous system, and colonizehs.
ures in six months.
the airways asymptomatically.19 Although the presence of
Nocardia has been detected in healthy individuals, the risk
is higher in patients with depressed cell-mediated immu-
nity, like patients with neoplastic disease and congenital or
acquired immunodeﬁciency (HIV infection).20 This bacterial
group has also been isolated in patients receiving treatment
with corticosteroids or immunosuppressive drugs, or hav-
ing lung disease, such as bronchiectasis, chronic obstructive
pulmonary disease, asthma, mycobacterial infection, tuber-
culosis, chronic granulomatosis, alveolar proteinosis or CF.21
The lung disease altering local airway defense mechanisms is
a known risk factor for nocardiosis. However, nocardiosis has
only been described sporadically in bronchiectasis and CF.7
In CF patients, the presence of microorganisms in sputum
cultures does not always imply a disease. There are few reports
in the literature that categorize Nocardia as colonizing bacte-
ria even in the absence of clinical ﬁndings.22 A signiﬁcant level
of nocardiosis is usually associated with clinical ﬁndings and
with a positive Gram-stain of respiratory specimens contain-
ing partially branching, acid-fast and Gram-positive bacteria.
Therefore, it would be convenient to include Gram staining
in the respiratory samples of CF patients, and if any organism
resembling Nocardia is observed, selective media culture plates
should be included followed by a longer incubation period.
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In our group of CF patients, the isolation of N. farcinica or
N. transvalensis was associated with pneumonia and a chronic
lung colonization, as previously reported,9,23,24 while the iso-
lation of N. veterana, N. pneumoniae and N. wallacei was related
with a transient colonization. N. pneumoniae and N. walla-
cei did not show any clinical relevance in our patients. This
fact, in addition with limited published data, does not allow
a deﬁnite evaluation of their pathogenicity. This study shows
that Nocardiae can cause lung colonization in cystic ﬁbrosis
patients, similar to other more  casual bacterial pathogens (e.g.,
P. aeruginosa or S. aureus).
The species-speciﬁc drug susceptibility pattern of Nocardia
and the multidrug resistant species isolated in our patients,
as N. farcinica, suggest that new molecular methods like 16S
rRNA gene sequencing for Nocardia identiﬁcation are crucial in
determining the need of a speciﬁc and individualized antibi-
otic treatment. On the other hand, identiﬁcation by standard
methods is a long process25 that can delay a timely antibiotic
therapy; therefore, the development of molecular methods
will facilitate a rapid diagnosis,26,27 epidemiological studies,
and the prompt initiation of the appropriate antibiotic therapy
in CF patients with clinical symptoms.
Nocardiosis is often difﬁcult to treat. The choice of therapy
should therefore be guided by in vitro susceptibility testing.
The situation can be further complicated as different strains of
the same species may display different antibiotic sensitivities.
However, a sulfonamide containing regimen is still con-
sidered as a treatment of choice, though some species show
in vitro resistance. Whether this is an indication of the treat-
ment failure needs further investigation.28
There are currently no guidelines as to when (immedi-
ately or not) and how Nocardia infections should be treated.
However, in the literature, treatments from 6 to 12 months
are recommended for serious lung infections or in patients
with strong immunosuppression. If symptoms are few, treat-
ment could be reduced to 1–3 months.6 When cystic ﬁbrosis
is involved, the duration of treatment is less deﬁned. But still
in such a case, for serious infections, treatment should also
last from 6 to 12 months; and if symptoms are few, it may be
spanned from 2 to 3 weeks, as in cases of exacerbations by
other microorganisms.4
Molecular techniques have made identiﬁcation of many
species of Nocardia more  rapid and precise providing data for
a better management of antibiotic treatment. Further stud-
ies involving a larger number of samples using molecular
methods27 are needed to determine the most common Nocar-
dia species and their role in lung infection or colonization in
CF patients. A high level of variations in the species and sus-
ceptibility patterns observed in such a small number of cases
require further attention. Usually, in Nocardia infection the ﬁrst
line of treatment is trimethoprim-sulfamethoxazole, but other
antibiotics, such as imipenem and amikacin, could be admin-
istered in severe infections in children with CF, as reported in
the literature.4Conﬂicts  of  interest
The authors declare no conﬂicts of interest. b i o l o g y 4 7 (2 0 1 6) 531–535
 e  f  e  r  e  n  c  e  s
1. Riordan JR, Rommens JM, Kerem B-S, et al. Identiﬁcation of
the cystic ﬁbrosis gene: cloning and characterization of
complementary DNA. Science.  1989;245:1066–1073.
2. Lyczak JB, Cannon CL, Pier GB. Lung infections associated
with cystic ﬁbrosis. Clin Microbiol Rev. 2002;15:194–222.
3. Thorn ST, Brown MA, Yanes JJ, et al. Pulmonary nocardiosis
in cystic ﬁbrosis. J Cyst Fibros. 2009;8:316–320.
4. Barrio MI, Martínez MC, Prados C, Girón RM, Maiz L, Martínez
MT. Isolation of Nocardia species patients with cystic ﬁbrosis.
Arch Bronconeumol. 2008;44:109–112.
5. Goss CH, Burns JL. Exacerbations in cystic ﬁbrosis. 1:
epidemiology and pathogenesis. Thorax.  2007;62:360–367.
6. Rodríguez-Nava V, Durupt S. A French multicentric study
and review of pulmonary Nocardia spp. in cystic ﬁbrosis
patients. Med Microbiol Immunol. 2014:1–12.
7. Lumb R, Greville H, Martin J, Sangster N, Colmes M. Nocardia
asteroides isolated from three patients with cystic ﬁbrosis.
Eur J Clin Microbiol Infect Dis.  2002;21:230–233.
8. LPSN-bacterio.net. http://www.bacterio.net/nocardia.html.
9.  Brown JM, McNeil MM. Nocardia, Rhodococcus,  Gorgonia,
Actinomadura,  Streptomyces, and other aerobic actinomycetes.
In:  Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Yolken RH,
eds.  Manual of Clinical Microbiology. 8th ed. Washington, DC:
ASM Press; 2007:502–531.
10. Nocard E. Note sur la maladie des boeufs de la Gouadeloupe
connue sous le nom de farcin. Ann Inst Pasteur.
1888;2:293–302.
11. Carrière C, Marchandin H, Andrieu JM, Vandome A, Pérez C.
Nocardia thyroiditis: unusual location of infection. J Clin
Microbiol.  1999;37:2323–2325.
12. Berd D. Laboratory identiﬁcation of clinically important
aerobic actinomycetes. Appl Microbiol. 1973;25:665–681.
13. Saubolle MA, Sussland D. Nocardiosis review of clinical and
laboratory experience. J Clin Microbiol. 2003;41:4497–4501.
14. Boiron P, Provost F, Dupont B. Technical protocols. In:
Methodes de laboratoire pour le diagnostic de la nocardiose. Paris,
France: Edited by Institut Pasteur; 1993:107–126.
15. Clinical and Laboratory Standards Institute Document
M24-A2. Susceptibility Testing of Mycobacteria, Nocardia, and
Other Aerobic Actinomycetes; Approved Standard. 2nd ed.
Wayne, PA: Clinical and Laboratory Standards Institute; 2011.
16. Rodríguez-Nava V, Couble A, Devulder G, Flandrois JP, Boiron
P,  Laurent F. Use of PCR-restriction enzyme pattern analysis
and  sequencing database for hsp65 gene-based identiﬁcation
of Nocardia species. J Clin Microbiol. 2006;44:536–546.
17. Brown-Elliott BA, Brown JM, Conville PS, Wallace RJ. Clinical
and laboratory features of the Nocardia spp. based on current
molecular taxonomy. Clin Microbiol Rev. 2006;19:259–282.
18. Torres OH, Domingo P, Pericas R, Boiron P, Montiel JA,
Vazquez G. Infection caused by Nocardia farcinica: case report
and review. Eur J Clin Microbiol Infect Dis.  2000;19:205–212.
19. Corti M, Villafane-Fiotti M. Nocardiosis: a review. Int J Infect
Dis.  2003;7:243–250.
20. Boiron P, Provost F, Chevrier G, Dupont B. Review of nocardial
infections in France 1987 to 1990. Eur J Clin Microbiol Infect Dis.
1992;11:709–714.
21. McNeil MM, Brown J. The medically important aerobic
actinomycetes: epidemiology and microbiology. Clin Microbiol
Rev.  1994;7:357–417.
22. Rosett W,  Hodges GR. Recent experiences with nocardial
infections. Am J Med Sci.  1978;276:279–285.23. Petersen BE, Jenkins SG, Yuan S, Lamm C, Szporn AH.
Nocardia farcinica isolated from bronchoalveolar lavage ﬂuid
of  a child with cystic ﬁbrosis. Pediatr Infect Dis J.
2007;26:858–859.
r o b i 
2005;43:1921–1924.
28. Brown-Elliott BA, Biehle J, Conville PS, et al. Sulfonamide
resistance in isolates of Nocardia spp. from a US multicenterb r a z i l i a n j o u r n a l o f m i c 
24. Bittar F, Stremler N, Audié JP, et al. Nocardia farcinica lung
infection in a patient with cystic ﬁbrosis: a case report. J Med
Case Rep. 2010;4:84.
25. Verroken A, Janssens M, Berhin C, et al. Evaluation of
matrix-assisted laser desorption ionization-time of ﬂight
mass spectrometry for identiﬁcation of Nocardia species. J
Clin Microbiol. 2010;48:4015–4021.
26. Conville PS, Brown JM, Steigerwalt AG, et al. Nocardia veterana
as a pathogen in North American patients. J Clin Microbiol.
2003;41:2560–2568.o l o g y 4 7 (2 0 1 6) 531–535 535
27. Couble A, Rodríguez-Nava V, de Montclos MP, Boiron P,
Laurent F. Direct detection of Nocardia spp. in clinical
samples by a rapid molecular method. J Clin Microbiol.survey. J Clin Microbiol. 2012;l50:670–672.
